Objectives: To assess the longer-term safety and efficacy of the IN.PACT Admiral (MDT-2113) drug-coated balloon (DCB) for the treatment of de novo and non-stented restenotic lesions in the superficial femoral and/or proximal popliteal arteries versus uncoated percutaneous transluminal angioplasty (PTA) in a Japanese cohort.
Bare metal stents (BMS) have demonstrated improved short-term outcomes compared to PTA, [5] [6] [7] [8] [9] with longer term patency rates of 60-75%. [10] [11] [12] However, in-stent restenosis (ISR) and stent fractures remain concerns. 1,2 Drug-eluting stents (DES) were developed to address this concern, and they too show improved outcomes compared to PTA. 13 While it is important to use a metal implant to support vessel scaffolding in the case of a dissection or other procedural complications, the progressive nature of PAD means that it is advantageous to the patient to avoid placing unnecessary stents that may limit future treatment.
Drug-coated balloons (DCBs) were developed to overcome the challenges of uncoated PTA alone and to avoid leaving an indwelling metal implant. Currently, DCBs used in the peripheral space use paclitaxel to prevent restenosis following treatment. Randomized and controlled trials have shown that DCBs are safe and effective to treat patients with femoropopliteal artery disease, and show improved outcomes compared to PTA. [14] [15] [16] [17] [18] [19] [20] [21] However, these trials are composed almost entirely of Caucasian patients. There is currently a paucity of longer term outcomes in this patient cohort, though there are several ongoing DCB trials studying in Asian populations (IN.PACT SFA China, NCT02118532; AcoArtI, NCT01850056; LTX DCB China, NCT02720003; Ranger China, NCT02944071; BIOLUX-P4 China, NCT02912715).
However, the clinical applications of these new technologies remain uncertain, and that uncertainty is magnified in non-Caucasian patients due to the lack of longer-term data. Additionally, complex lesions are sometimes a challenge to treat with a standalone device.
As such, understanding the appropriate use of DCBs in a landscape that includes DES and newer devices, such as atherectomy, will remain essential moving forward.
Recently, the 1-year results of the IN.PACT SFA Japan study were reported, showing high patency and low rates of clinically driven target lesion revascularization (CD-TLR) in a Japanese population. 22 In this report, longer term data is shared for the IN.PACT SFA Japan trial (MDT-2113) out to 2 years.
| MATERIALS AND METHODS

| Study design
IN.PACT SFA Japan was a Phase III trial conducted in Japan, and the methods are more fully reported in the published 1-year results of this study. 22 This multicenter, prospective, randomized, single-blinded trial 
| Patient population
Patients were between the ages of 20 and 85, with symptoms of claudication and/or ischemic rest pain (Rutherford Clinical Category 2-4) with a superficial femoral and/or proximal popliteal artery lesion stenosis severity of 70-99%. Total lesion length was between 4 cm and 20 cm for stenotic lesions, or ≤10 cm for those lesions that were fully occluded.
Lesions were characterized as TASC A-C, and lesions were required to undergo successful pre-dilatation before inclusion in the trial. Prior to enrollment, written informed consent was obtained from all patients according to the protocols approved by the institutional review boards at each investigational site. Patients were randomly assigned in a 2:1 ratio to treatment with a DCB (n = 68) or PTA (n = 32).
The trial included independent oversight by a Data Safety
Monitoring Board. A Clinical Events Committee (CEC) reviewed and adjudicated all major adverse events (MAEs). Independent core laboratories analyzed procedural and follow-up images and included duplex ultrasound (DUS; VasCore, Massachusetts General Hospital, Boston, MA, USA) and angiography (SynvaCor, Springfield, IL, USA).
The CEC and independent core laboratories were blinded and will remain blinded to the treatment assignments through the 36-month follow-up duration. The trial was conducted in accordance with the Declaration of Helsinki, Good Clinical Practice Guidelines, and applicable laws as specified by all relevant governmental authorities. Heparin was administered at the time of the procedure to maintain an activated clotting time of 250 sec. Investigators were instructed to follow the IFU. Post-dilatation with a standard uncoated PTA balloon was allowed at the discretion of the operator. In both treatment groups, provisional stenting was allowed following PTA failure. PTA failure was defined as a residual stenosis of 50% or major (≥Grade D) flow-limiting dissection confirmed by a peak translesional gradient >10 mmHg that remained unresolved following repeated and prolonged PTA inflations.
| Treatment and medical therapy
In both arms, post-procedure medical therapy included aspirin at a minimum of 81 mg daily (for a minimum of 6 months) and clopidogrel daily for a minimum duration of 1 month for nonstented patients and 3 months for patients who received stents.
| Follow-up
Patients were followed by the treating physician at 30 days, 6 months, 12 months, and 24 months, including office visits with DUS, functional testing, and adverse event assessment. If a reintervention was required within 12 months of the procedure, it was performed according to standard practice using PTA balloons and provisional stenting. 
| Statistical analysis
The planned enrollment of 100 subjects was not independently powered;
however, the trial design and endpoint assessments were the same as the All analyses were based on the intent to treat principle. For baseline characteristics, continuous variables were described as mean AE standard deviation and were compared by t-tests; dichotomous and categorical variables were described as counts and proportions and were compared by Fisher's exact test or Cochran-Mantel-Haenszel (CMH) test, respectively. The Kaplan-Meier method was used to evaluate time-to-event data for primary patency over the 24-month followup period. The difference in the survival curves between groups was assessed using the log-rank test. The same analysis was also employed for CD-TLR. For other outcomes, in addition to the descriptive statistics, Fisher's exact test was employed for binary outcomes and ttest for continuous outcomes. In addition, a forest plot was created to explore the treatment effect in primary patency for selected subgroups. For all endpoints, the level of statistical significance was set at P < 0.05 with no correction for multiple comparisons. Statistical analyses were performed using SAS (SAS Institute, North Carolina, USA) version 9.4.
3 | RESULTS
| Baseline and procedural characteristics
One hundred patients (68 in the DCB group and 32 in the PTA group)
were enrolled at 11 centers in Japan between September 2013 and 
| Efficacy outcomes
Primary patency through 24 months was 79.8% in the DCB arm and 46.9% in the PTA arm (log-rank P < 0.001, Figure 2 ). Freedom from CD-TLR as determined by the Kaplan-Meier analysis was 90.8% in the DCB arm through 2 years compared to a value of 81.3% in the PTA arm (log-rank P = 0.114; Figure 3 ). The proportion rate of CD- 
FIGURE 2
The Kaplan-Meier estimate of primary patency through 24 months. Primary patency by the Kaplan-Meier estimate was significantly higher in the DCB group compared with PTA group (P < 0.001). Bars represent 95% confidence intervals. All TLR events were adjudicated by the independent and blinded CEC and all ultrasound and angiographic images were analyzed by independent and blinded core laboratories. DCB, drug-coated balloon; PTA, percutaneous transluminal angioplasty; CEC, Clinical Events Committee TLR at 2 years was 9.1% in the DCB arm (6/66 patients) and 20.7% in the PTA arm (6/29 patients; P = 0.117; see Table 3 ). The mean time to first CD-TLR was 470.2 AE 199.8 days in the DCB arm and 168.2 AE 65.4 days in the PTA arm (P = 0.012). Similar primary sustained clinical improvement, defined as freedom from target limb amputation, TVR, and an increase in at least one Rutherford class, was seen in both arms (P = 0.795; see Table 3 ). Males appear to respond better to treatment with a DCB, with a primary patency rate of 84.8% through 24 months compared to 66.7% in women.
| Safety outcomes
Safety outcomes through 24 months are reported in Table 3 . The primary safety composite endpoint of freedom from 30-day device and
Freedom from clinically driven target lesion revascularization through 24 months. Freedom from clinically driven target lesion revascularization were not statistically different between the DCB group and the PTA group (P = 0.114). Bars represent 95% confidence intervals. All TLR events were adjudicated by the independent and blinded CEC. DCB, drug-coated balloon; PTA, percutaneous transluminal angioplasty; CEC, Clinical Events Committee Abbreviations: TLR, target lesion revascularization; TVR, target lesion revascularization; DCB, drug-coated balloon; N, numbers in category; n, number of available values; PTA, percutaneous transluminal angioplasty; CD-TLR, clinically-driven TLR. a Clinically driven TLR is defined as any re-intervention within the target vessel due to symptoms or drop of ABI/TBI of ≥20% or >0.15 when compared to post-procedure baseline ABI/TBI. b All TLR includes clinically driven and incidental or duplex-driven TLR. c Primary sustained clinical improvement defined as freedom from target limb amputation, TVR, and increase in Rutherford class at 12 months post-procedure. d Primary safety composite is defined as freedom from device and procedure-related 30-day death and freedom from target limb major amputation and clinically-driven TVR through 24 months. e MAE is defined as a composite of target limb major amputation, clinically-driven TVR, all-cause death, and thrombosis within 24 months.
procedure-related death and target limb major amputation and CD-TVR within 24 months was 89.4% in the DCB group versus 79.3% in the PTA group (P = 0.207). There were no major target limb amputations or thromboses through 24 months in either group. The four deaths in the DCB group were due to oropharyngeal cancer, pneumonia, lung adenocarcinoma, and small cell lung cancer. The one death in the PTA group was due to pneumonia. All deaths were adjudicated as not procedure-or device-related by the CEC.
| Functional outcomes
At 24 months, both treatment groups showed improvement in all measured functional outcomes (Table 4) . Changes in the six-month walking test, WIQ, and EQ-5D index were similar between cohorts.
However, ABI/TBI values were statistically significantly higher in the PTA arm at 24 months (0.945) compared to the DCB arm (0.883; P = 0.047).
| DISCUSSION
Randomized trials have demonstrated the superiority of DCB compared to PTA in patients with femoropopliteal PAD. 14, 15, [17] [18] [19] [20] [21] Though important as a starting place to determine the safety and efficacy of a given device, the subjects studied in these trials are overwhelmingly of Caucasian race. These results are the first longer term RCT data describing the safety and efficacy of a DCB in a Japanese population.
This study increases the evidence supporting use of a DCB to prevent restenosis and avoid leaving a metal implant behind.
Results of endovascular treatment in Japanese patients have been reported previously, and mainly focus on stent deployment, whether treatment devices are BMS or DES. 66.7%). 15 As such, the question of outcomes by sex merits further investigation in a Japanese population. The CD-TLR rate in both studies was the same: 9.1%. When comparing patients in this trial to other IDE trials, Japanese patients are older and more likely to be diabetic. 15, 17, 20, 21 The mean lesion length in the DCB arm of When comparing trials both in Japan and across the globe, it is clear that both DCBs and DES will play a role in future treatment of Japan studying different devices, and will also contribute to the development of an optimal treatment algorithm for Japanese patients, and include bio-mimetic stents, atherectomy, covered stents, and other DCBs (MIMICS-2, NCT02400905; J-Supreme, NCT02733653; Gore VJH 11-01, NCT01575808; and RANGER II SFA, NCT03064126).
| LIMITATIONS
This study was smaller than other studies in the IN.PACT DCB clinical program and was not independently powered, yet adds an important data point in the generalizability of results across patient populations and lesion types. No economic data were gathered during this study, and no specific guidelines for other treatments were provided other than following standard of care. Finally, patients will only be followed out to 3 years.
| CONCLUSION
Results from the IN.PACT SFA Japan Trial showed significantly higher patency rates and lower CD-TLR rates out to 2 years following treatment with an IN.PACT Admiral DCB. There was a favorable treatment effect comparing DCB to treatment with PTA. These results demonstrate the safety and efficacy of this DCB in an Asian population.
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